The Republic of Gabon became the fourteenth (14th) member state deposited the instrument of ratification of the African Medicines Agency (AMA) to the AU Commission on 4th October 2021 after ratifying it on the 1st October 2021 in Libreville, Gabon. H.E. Amira Elfadil Mohammed, Commissioner for Health, Humanitarian Affairs and Social Development, at the AU Commission received the instrument from the Ambassador of Gabon to Ethiopia and the African Union Amb. Hermann Imongault.
AMA aims to provide support for the improvement of weak regulatory systems. AMA will, among other functions, coordinate and strengthen ongoing initiatives to harmonize medical products regulation and enhance the competence of Good Manufacturing Practices (GMP) inspectors to do so. The Agency will further coordinate the collection, management, storage and sharing of information on all medical products including substandard and falsified medical products, with all its States Parties and globally.
To date, eighteen (18) member states have ratified the AMA Treaty and fourteen (14) of these have deposited the instruments of ratification to the Commission. The AMA Treaty will enter into Force 30 days upon the deposit of the 15th instrument of ratification at the Commission.
Pending the deposit of the 15th instrument of ratification, the Commission has invited member states to submit proposals for the hosting of the Africa Medicines Agency Headquarters. The Commission has also further extended the deadline for submission of interest to host the AMA up to 15th October 2021, as per the ruling of the Permanent Representatives Committee (PRC) on 6th September 2021. The Commission expects to have the established AMA in 2022.
The African Union Commission encourages all its Member States to sign and ratify the Treaty for the establishment of AMA in the interest of public health, safety and security. The Treaty is available for signature at the Headquarters of the Commission in Addis Ababa, Ethiopia.
Distributed by APO Group on behalf of African Union (AU).
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
